Most of the knowledge in pediatric antiphospholipid syndrome (APS) is derived from studies performed on the adult population. As in adults, antiphospholipid antibodies (aPL) can contribute to thrombosis, especially cerebrovascular thrombosis, in neonates and children. Since aPL have the potential to cross the placental barrier, and since the pediatric population is prone to infections, re-testing for their positivity is essential to specify their role in cerebrovascular thrombosis.
In this review, we aimed at assessing the prevalence of aPL, criteria or non-criteria, in neonatal and childhood ischemic stroke and sinovenous thrombosis trying to find an association between aPL and cerebrovascular thrombosis in the neonatal and pediatric population. Also, we looked into the effect of aPL and anticoagulants/antiplatelets on the long term neurological outcomes of affected neonates or children. The questions regarding the prevalence of aPL among pediatric patients with cerebrovascular thrombosis, the relationship between the titers of aPL and incidence and recurrence of cerebrovascular events, the predictability of the long term neurological outcomes, and the most optimal anticoagulation plan are still to be answered. However, it is crucial for clinicians to screen neonates and children with cerebrovascular thrombosis for aPL and confirm their presence if positive.
MiyakisSLockshinMDAtsumiT, et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006;
4: 295–306.
3.
AvcinTCimazRSilvermanED, et al.
Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics2008;
122: e1100–e1107.
4.
WincupCIoannouY.The differences between childhood and adult onset antiphospholipid syndrome. Front Pediatr2018;
6: 362.
5.
AvcinTSilvermanED.Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus2007;
16: 627–633.
6.
Manco-JohnsonMJNussRKeyN, et al.
Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr1996;
128: 319–323.
7.
GuptaMJohann-LiangRBusselJBGersonyWMLehmanTJ.Elevated IgA and IgM anticardiolipin antibodies in acute Kawasaki disease. Cardiology2002;
97: 180–182.
8.
AmbrozicAAvicinTIchikawaK, et al.
Anti-beta(2)-glycoprotein I antibodies in children with atopic dermatitis. Int Immunol2002;
14: 823–830.
9.
WaheziDIlowiteNWuX, et al.; for the Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators.
Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of 2-glycoprotein I. Lupus2013;
22: 702–711.
10.
KorematsuSYamadaHMiyaharaHIharaK.Increased levels of anti-phosphatidylcholine and anti-phosphatidylethanolamine antibodies in pediatric patients with cerebral infarction. Brain Dev2017;
39: 542–546.
11.
KorematsuSGotoHGotohCOhkiRKubotaTIzumiT.Central retinal vein occlusion in a pediatric patient with SLE and antiphospholipid antibodies without anti-cardiolipin or anti-β2 glycoprotein I antibodies. BMC Pediatr2014;
14: 116.
12.
DriestKDSturmMSO’BrienSH; for the CARRA Registry Investigators.Factors associated with thrombosis in pediatric patients with systemic lupus erythematosus. Lupus2016;
25: 749–753.
13.
Rego SousaPFigueiraRVasconcellosR.Neonatal stroke associated with de novo antiphospholipid antibody and homozygous 1298C/C methylenetetrahydrofolate reductase mutation. BMJ Case Rep2012;
2012: bcr2012006451.
14.
MuscalEBreyRL.Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus2010;
19: 406–411.
15.
SimchenMJGoldsteinGLubetskyAStraussTSchiffEKenetG.Factor v Leiden and antiphospholipid antibodies in either mothers or infants increase the risk for perinatal arterial ischemic stroke. Stroke2009;
40: 65–70.
16.
PilarskaELemkaMBakowskaA.Prothrombotic risk factors in ischemic stroke and migraine in children. Acta Neurol Scand2006;
114: 13–16.
17.
MakhijaSAnejaSTripathiRPNarayanS.Etiological profile of stroke and its relation with prothrombotic states. Indian J Pediatr2008;
75: 579–584.
18.
KenetGSadetzkiSMuradH, et al.
Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke2000;
31: 1283–1288.
19.
FerrieroDMFullertonHJBernardTJ, et al.; American Heart Association Stroke Council and Council on Cardiovascular and Stroke Nursing.Management of stroke in neonates and children: a scientific statement from the American Heart Association/American Stroke Association. Stroke2019;
50: e51–e96.
20.
MallickAAGanesanVKirkhamFJ, et al.
Childhood arterial ischaemic stroke incidence, presenting features, and risk factors: a prospective population-based study. Lancet Neurol2014;
13: 35–43.
CareySWrogemannJBoothFARafayMF.Epidemiology, clinical presentation, and prognosis of posterior circulation ischemic stroke in children. Pediatr Neurol2017;
74: 41–50.
23.
RottaNTda SilvaARda SilvaFL, et al.
Cerebrovascular disease in pediatric patients. Arq Neuropsiquiatr2002;
60: 959–963.
24.
MattaAPGalvaoKROliveiraBS.Cerebrovascular disorders in childhood: etiology, clinical presentation, and neuroimaging findings in a case series study. Arq Neuropsiquiatr2006;
64: 181–185.
25.
DelsingBJCatsman-BerrevoetsCEAppelIM.Early prognostic indicators of outcome in ischemic childhood stroke. Pediatr Neurol2001;
24: 283–289.
26.
RanzanJRottaNT.Ischemic stroke in children: a study of the associated alterations. Arq Neuropsiquiatr2004;
62: 618–625.
27.
deVeberGAndrewMAdamsC, et al.; Canadian Pediatric Ischemic Stroke Study Group.Cerebral sinovenous thrombosis in children. N Engl J Med2001;
345: 417–423.
28.
FitzgeraldKCWilliamsLSGargBPCarvalhoKSGolombMR.Cerebral sinovenous thrombosis in the neonate. Arch Neurol2006;
63: 405–409.
29.
TeksamMMoharirMDeveberGShroffM.Frequency and topographic distribution of brain lesions in pediatric cerebral venous thrombosis. AJNR Am J Neuroradiol2008;
29: 1961–1965.
30.
HellerCHeineckeAJunkerR, et al.; the Childhood Stroke Study Group.
Cerebral venous thrombosis in children: a multifactorial origin. Circulation2003;
108: 1362–1367.
31.
WasayMDaiAIAnsariMShaikhZRoachES.Cerebral venous sinus thrombosis in children: a multicenter cohort from the United States. J Child Neurol2008;
23: 26–31.
32.
MaleCLechnerKEichingerS, et al.
Clinical significance of lupus anticoagulants in children. J Pediatr1999;
134: 199–205.
33.
UthmanIWGharaviAE.Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum2002;
31: 256–263.
34.
KallanagowdarCChauhanAPuertolasMVWarrierR.Prevalence and resolution of lupus anticoagulant in children. Ochsner J2016;
16: 172–175.
35.
SinghAKRaoKPKizerJLazarchickJ.Lupus anticoagulants in children. Ann Clin Lab Sci1988;
18: 384–387.
36.
BerkunYPadehSBarashJ, et al.
Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum2006;
55: 850–855.
37.
ZurgilNBakimerRTincaniA, et al.
Detection of anti-phospholipid and anti-DNA antibodies and their idiotypes in newborns of mothers with anti-phospholipid syndrome and SLE. Lupus1993;
2(1_suppl): 233–237.
38.
de KlerkOLde VriesTWSinnigeLG.An unusual cause of neonatal seizures in a newborn infant. Pediatrics1997;
100: E8.
39.
BerfeloFJKersbergenKJvan OmmenCH, et al.
Neonatal cerebral sinovenous thrombosis from symptom to outcome. Stroke2010;
41: 1382–1388.
40.
MeroniPLTincaniASeppN, et al.
Endothelium and the brain in CNS lupus. Lupus2003;
12: 919–928.
41.
SinclairAJFoxCKIchordRN, et al.
Stroke in children with cardiac disease: report from the international pediatric stroke study group symposium. Pediatr Neurol2015;
52: 5–15.
42.
BonduelMSciuccatiGHepnerM, et al.
Arterial ischemic stroke and cerebral venous thrombosis in children: a 12-year Argentinean registry. Acta Haematol2006;
115: 180–185.
43.
BalasaVGruppoRADeGrauwA, et al.
#511 Pediatric stroke and thrombophilia: a retrospective study. Thrombosis and Haemostasis1998;
20: 370.
44.
AngeliniLRavelliACaporaliRRumiVNardocciNMartiniA.High prevalence of antiphospholipid antibodies in children with idiopathic cerebral ischemia. Pediatrics1994;
94: 500–503.
45.
BerkunYSimchenMJStraussTMenashcuSPadehSKenetG.Antiphospholipid antibodies in neonates with stroke – a unique entity or variant of antiphospholipid syndrome?Lupus2014;
23: 986–993.
46.
GattornoMFalciniFRavelliA, et al.
Outcome of primary antiphospholipid syndrome in childhood. Lupus2003;
12: 449–453.
47.
YasutomiMEgawaHKobayashiYOikeFTanakaK.Living donor liver transplantation for Budd-Chiari syndrome with inferior vena cava obstruction and associated antiphospholipid antibody syndrome. J Pediatr Surg2001;
36: 659–662.
48.
UnverOEkinciGKutlubayBI, et al.
Evaluation of cases with cerebral thrombosis in children. Turk Pediatri Ars2016;
51: 87–93.
49.
KenetGWaldmanDLubetskyA, et al.
Paediatric cerebral sinus vein thrombosis. A multi-center, case-controlled study. Thromb Haemost2004;
92: 713–718.
ZurgilNBakimerRTincaniA, et al.
Detection of anti-phospholipid and anti-DNA antibodies and their idiotypes in newborns of mothers with anti-phospholipid syndrome and SLE. Lupus1993;
2: 233–237.
52.
MottaMChiricoGRebaioliCB, et al.
Anticardiolipin and anti-beta2 glycoprotein I antibodies in infants born to mothers with antiphospholipid antibody-positive autoimmune disease: a follow-up study. Am J Perinatol2006;
23: 247–251.
AkanliLFTrasiSSThuraisamyK, et al.
Neonatal middle cerebral artery infarction: association with elevated maternal anticardiolipin antibodies. Am J Perinatol1998;
15: 399–402.
55.
ChowGMellorD.Neonatal cerebral ischaemia with elevated maternal and infant anticardiolipin antibodies. Dev Med Child Neurol2000;
42: 412–413.
56.
Paro-PanjanDKitanovskiLAvcinT.Neonatal antiphospholipid syndrome associated with heterozygous methylentetrahydrofolate reductase C677T and prothrombin G20210A gene mutations. Rheumatology (Oxford)2007;
46: 720–721.
57.
MerlinEDoréEChabrierSBiardMMarques-VerdierAStéphanJ-L.A case of infantile de novo primary antiphospholipid syndrome revealed by a neonatal arterial ischemic stroke. J Child Neurol2012;
27: 1340–1342.
58.
58.GianiTMauroAFerraraGCimazR.Case report: infantile ischemic stroke and antiphospholipid antibodies, description of four cases. Front Pediatr2020;
8: 596386.
59.
KurnikKKoschAStraterRSchobessRHellerCNowak-GottlU; Childhood Stroke Study Group.Recurrent thromboembolism in infants and children suffering from symptomatic neonatal arterial stroke: a prospective follow-up study. Stroke2003;
34: 2887–2892.
60.
De CarolisMPSalviSBersaniIDe CarolisS.Isolated cerebral sinovenous thrombosis: a rare case of neonatal antiphospholipid syndrome. Indian Pediatr2012;
49: 411–412.
61.
IchordRNBenedictSLChanAKKirkhamFJNowak-GöttlU; International Paediatric Stroke Study Group,Nowak-Gottl U, International Paediatric Stroke Study G. Paediatric cerebral sinovenous thrombosis: findings of the international paediatric stroke study. Arch Dis Child2015;
100: 174–179.
62.
GalliMLucianiDBertoliniGBarbuiT.Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood2003;
101: 1827–1832.
63.
OtomoKAtsumiTAmengualO, et al.
Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum2012;
64: 504–512.
64.
AlshekailiJReynoldsGCookMC.De novo infantile primary antiphospholipid antibody syndrome. Lupus2010;
19: 1565–1568.
65.
CabralMAbadessoCCondeMAlmeidaHCarreiroH.Catastrophic antiphospholipid syndrome: first signs in the neonatal period. Eur J Pediatr2011;
170: 1577–1583.
66.
SträterRVielhaberHKassenböhmerRvon KriesRGöbelUNowak-GöttlU.Genetic risk factors of thrombophilia in ischaemic childhood stroke of cardiac origin. A prospective ESPED survey. Eur J Pediatr1999;
158 Suppl 3: S122–125.
67.
DuranRBinerBDemirMCeltikCKarasalihogluS.Factor V Leiden mutation and other thrombophilia markers in childhood ischemic stroke. Clin Appl Thromb Hemost2005;
11: 83–88.
68.
Leniček KrležaJÐuranovićVBronićACoen HerakDMejaški-BošnjakVZadroR.Multiple presence of prothrombotic risk factors in Croatian children with arterial ischemic stroke and transient ischemic attack. Croat Med J2013;
54: 346–354.
69.
TuhrimSRandJHWuX-X, et al.
Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke1999;
30: 1561–1565.
70.
von SchevenEAthreyaBHRoseCDGoldsmithDPMortonL.Clinical characteristics of antiphospholipid antibody syndrome in children. J Pediatr1996;
129: 339–345.
71.
RidhaFErzurumSA.Cerebral venous thrombosis masquerading as pseudotumour cerebri in a paediatric patient. J Paediatr Child Health 2014; 50: 419.
72.
ShiWKrilisSAChongBHGordonSChestermanCN.Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med1990;
20: 231–236.
73.
AvcinTAmbrozicAKuharMKvederTRozmanB.Anticardiolipin and anti-beta(2) glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology (Oxford)2001;
40: 565–573.
74.
EbelingFPetajaJAlankoS, et al.
Infant stroke and beta-2-glycoprotein 1 antibodies: six cases. Eur J Pediatr2003;
162: 678–681.
75.
DucloyerJBMichelLWiertlewskiSLebranchuP.Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein. Eur J Ophthalmol2019;
29: 257–261.
76.
NagaiSHorieYAkaiTTakedaSTakakuA.Superior sagittal sinus thrombosis associated with primary antiphospholipid syndrome – case report. Neurol Med Chir (Tokyo)1998;
38: 34–39.
77.
CookRPMarquesMOsterR.Clinical significance of lupus anticoagulant and anti-Beta2 glycoprotein I antibodies in a pediatric cohort. Blood2009;
114: 3989–3989.
78.
MassengillSFHedrickCAyoubEMSleasmanJWKaoKJ.Antiphospholipid antibodies in pediatric lupus nephritis. Am J Kid Dis1997;
29: 355–361.
79.
ChakrabortyMKotechaS.Pulmonary surfactant in newborn infants and children. Breathe2013;
9: 476–488.
80.
LevineJSBranchDWRauchJ.The antiphospholipid syndrome. New England Journal of Medicine2002;
346: 752–763.
81.
BerardMChantomeRMarcelliABoffaMC.Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol1996;
23: 1369–1374.
82.
KorematsuSGotoHGotohCOhkiRKubotaTIzumiTJBp.Central retinal vein occlusion in a pediatric patient with SLE and antiphospholipid antibodies without anti-cardiolipin or anti-β2 glycoprotein I antibodies. BMC Pediatrics2014;
14: 1–3.
83.
RoachESGolombMRAdamsR, et al.
Management of stroke in infants and children: a scientific statement from a special writing group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease IN THE Young. Stroke2008;
39: 2644–2691.
84.
GigliaTMMassicotteMPTweddellJS, et al.; American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Stroke Council.
Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. Circulation2013;
128: 2622–2703.
85.
GolombMRSahaCGargBPAzzouzFWilliamsLS.Association of cerebral palsy with other disabilities in children with perinatal arterial ischemic stroke. Pediatr Neurol2007;
37: 245–249.
86.
BosenbarkDDKrivitzkyLIchordR, et al.
Clinical predictors of attention and executive functioning outcomes in children after perinatal arterial ischemic stroke. Pediatr Neurol2017;
69: 79–86.
87.
GruntSMazenauerLBuerkiSE, et al.
Incidence and outcomes of symptomatic neonatal arterial ischemic stroke. Pediatrics2015;
135: e1220–e1228.
88.
BoffaMCLachassinneE.Infant perinatal thrombosis and antiphospholipid antibodies: a review. Lupus2007;
16: 634–641.
89.
PeixotoMVde CarvalhoJFRodriguesCE.Clinical, laboratory, and therapeutic analyses of 21 patients with neonatal thrombosis and antiphospholipid antibodies: a literature review. J Immunol Res2014;
2014: 672603.
90.
MonaglePNewallF.Management of thrombosis in children and neonates: practical use of anticoagulants in children. Hematology Am Soc Hematol Educ Program2018;
2018: 399–404.
